TrialCancer science2018

Bortezomib plus dexamethasone vs thalidomide plus dexamethasone for relapsed or refractory multiple myeloma.

Shinsuke Iida et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.